Ratings by Goldman Sachs (Asad Haider)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/7/2026 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 5/4/2026 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 4/30/2026 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 2/26/2026 | Vaxcyte | PCVX | Maintain | Neutral (N/A) |
|
Details | ||
| 2/13/2026 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 2/5/2026 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 1/28/2026 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 1/23/2026 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 1/16/2026 | BioNTech | BNTX | Upgrade | Buy (Neutral) |
106.07 (92.43) |
-12.86% | Details | |
| 12/18/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 11/6/2025 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 11/5/2025 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 10/8/2025 | Johnson & Johnson | JNJ | Maintain | Conviction Buy (N/A) |
|
Details | ||
| 9/30/2025 | Inova Technology, Inc. | INVA | New Coverage | Sell (N/A) |
19.03 (21.70) |
14.03% | Details | |
| 9/30/2025 | Royalty Pharma | RPRX | New Coverage | Buy (N/A) |
35.25 (60.12) |
70.55% | Details | |
| 9/22/2025 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 9/19/2025 | Johnson & Johnson | JNJ | Maintain | Conviction Buy (N/A) |
|
Details | ||
| 9/12/2025 | Vaxcyte | PCVX | New Coverage | Neutral (N/A) |
33.06 (53.17) |
60.83% | Details | |
| 7/17/2025 | NewAmsterdam Pharma Co NV | NAMS | New Coverage | Neutral (N/A) |
20.92 (27.70) |
32.41% | Details | |
| 7/17/2025 | Johnson & Johnson | JNJ | Maintain | Buy (N/A) |
|
Details | ||
| 7/10/2025 | Johnson & Johnson | JNJ | Maintain | Conviction Buy (N/A) |
|
Details | ||
| 6/3/2025 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 5/29/2025 | BioNTech | BNTX | New Coverage | Neutral (N/A) |
97.53 (106.07) |
8.76% | Details | |
| 4/28/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 4/21/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 4/8/2025 | Merck | MRK | New Coverage | Buy (N/A) |
81.47 (131.73) |
61.69% | Details | |
| 4/8/2025 | Abbvie | ABBV | New Coverage | Neutral (N/A) |
186.96 (266.83) |
42.72% | Details | |
| 4/8/2025 | Bristol-Myers Squibb Co. | BMY | Downgrade | Neutral (Buy) |
55.30 (63.78) |
15.33% | Details | |
| 4/8/2025 | Eli Lilly | LLY | Upgrade | Buy (Neutral) |
738.21 (1220.76) |
65.37% | Details | |
| 4/8/2025 | Pfizer | PFE | Downgrade | Neutral (Buy) |
22.97 (25.33) |
10.27% | Details | |
| 4/8/2025 | Johnson & Johnson | JNJ | Upgrade | Buy (Neutral) |
153.24 (267.77) |
74.74% | Details | |
| 12/14/2018 | ICON plc | ICLR | Downgrade | Buy (Conviction Buy) |
138.11 (318.08) |
130.31% | Details |
